GLP1 receptor agonists and their role in the therapy of neurodegenerative diseases - a literature review
DOI:
https://doi.org/10.12775/QS.2026.51.68584Keywords
Alzheimer disease, Neurodegeneration, GLP-1 analogues, Liraglutide, Dementia, tau, diabetesAbstract
Introduction: GLP-1 receptor agonists (GLP-1RAs) are drugs used in the treatment of type 2 diabetes and obesity, and are believed to have potential neuroprotective properties. Decreased glucose metabolism in the brain, the development of neuronal insulin resistance, and abnormal tau protein phosphorylation and amyloid-β deposition all play important roles in the pathogenesis of Alzheimer's disease (AD). Numerous preclinical studies in animal models have demonstrated that GLP-1 analogs, such as liraglutide and lixisenatide, are capable of crossing the blood-brain barrier, stimulating neurogenesis, limiting tau hyperphosphorylation, reducing amyloid-β deposition, and improving synaptic and cognitive functions. Data from clinical and observational studies suggest that GLP-1RA use in patients with type 2 diabetes is associated with a reduced risk of developing dementia, including AD. In large retrospective analyses, semaglutide therapy reduced the likelihood of a first diagnosis of Alzheimer's disease by 40–70% compared with other antidiabetic agents. In a randomized trial, liraglutide prevented the decline in brain glucose metabolism in patients with AD, but had no significant effect on amyloid-β levels or cognitive function.
Review methods: A comprehensive analysis of research papers available on PubMed and Google Scholar was conducted using keywords: Alzheimer's disease, neurodegeneration, GLP-1 analogues, liraglutide, dementia, tau, diabetes, obesity
Conclusion: Accumulating evidence suggests that GLP-1 agonists may be a promising therapeutic option for the prevention and treatment of neurodegenerative diseases. However, further randomized clinical trials are necessary to confirm their efficacy in patients with Alzheimer's disease.
Keywords: Alzheimer's disease, neurodegeneration, GLP-1 analogues, liraglutide, dementia, tau, diabetes, obesity
References
1. Gejl M, Gjedde A, Egefjord L, Møller A, Hansen SB, Vang K, Rodell A, Brændgaard H, Gottrup H, Schacht A, Møller N, Brock B, Rungby J. In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Front Aging Neurosci. 2016 May 24;8:108. doi: 10.3389/fnagi.2016.00108. PMID: 27252647; PMCID: PMC4877513.
2. Gejl M, Gjedde A, Egefjord L, Møller A, Hansen SB, Vang K, et al. In Alzheimer’s disease, 6‑month treatment with GLP‑1 analog prevents decline of brain glucose metabolism: randomized, placebo‑controlled, double‑blind clinical trial. Front Aging Neurosci. 2016;8:108. doi:10.3389/fnagi.2016.00108
3. Xu R, Wang W, Wang QQ, Gurney M, Perry G, Volkow ND, et al. Associations of semaglutide with first‑time diagnosis of Alzheimer’s disease in patients with type 2 diabetes: Target trial emulation using nationwide real‑world data in the US. Alzheimers Dement. 2024;20(12):8661‑72. doi:10.1002/alz.14313
4. McClean PL, Hölscher C. Neuroprotective effects of lixisenatide in the APP/PS1 mouse model of Alzheimer’s disease. Neuropharmacology. 2014;91:241‑52. doi:10.1016/j.neuropharm.2014.11.004
5. Andrea E. Cavanna, Michael R. Trimble, The precuneus: a review of its functional anatomy and behavioural correlates, Brain, Volume 129, Issue 3, March 2006, Pages 564–583
6. Mingyang Sun, Xiaoling Wang, Zhongyuan Lu, Yitian Yang, Shuang Lv, Mengrong Miao, Wan-Ming Chen, Szu Yuan Wu, Jiaqiang Zhang - Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes: BMJ Open Diabetes Research & Care 2025;13:e004902.
7. Lin H, Tsai Y, Liao P, Wei JC. Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity. JAMA Netw Open. 2025;8(7):e2521016. doi:10.1001/jamanetworkopen.2025.21016
8. Seminer A, Mulihano A, O’Brien C, Krewer F, Costello M, Judge C, et al. Cardioprotective glucose-lowering agents and dementia risk: A systematic review and meta-analysis. JAMA Neurol. 2025;82(5):450‑460. doi:10.1001/jamaneurol.2025.0360
9. McClean PA, Hölscher C. Neuroprotective effects of lixisenatide in the APP/PS1 mouse model of Alzheimer’s disease. Neuropharmacology. 2014;91:241‑252. doi:10.1016/j.neuropharm.2014.11.004
10. McClean PL, Hölscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology. 2014;76(Pt A):57‑67. doi:10.1016/j.neuropharm.2013.08.005
11. Parthsarathy V, Hölscher C. Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PLoS One. 2013;8(3):e58784. doi:10.1371/journal.pone.0058784.
12. Hansen HH, Barkholt P, Fabricius K, Jelsing J, Terwel D, Pyke C, Knudsen LB, Vrang N. The GLP‑1 receptor agonist liraglutide reduces pathology‑specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. Brain Res. 2016;1634:158‑170. doi:10.1016/j.brainres.2015.12.033. PMID:26746341.
13. Ma DL, Nie H, Fu J, Yuan Z, Wang R, Sun J, et al. Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice. J Neurochem. 2015;135(2):301‑8. doi:10.1111/jnc.13248
14. Ma D-L, Yang Y, Song W, Zhang M, Hu S, Shao S, Gong C-X. Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice. J Neurochem. 2015;135(2):301-308. doi:10.1111/jnc.13248
15. Carranza‑Naval MJ, del Marco A, Hierro‑Bujalance C, Alves‑Martínez P, Infante‑Garcia C, Vargas‑Soria M, et al. Liraglutide reduces vascular damage, neuronal loss, and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes. Front Aging Neurosci. 2021;13:741923. doi:10.3389/fnagi.2021.741923.
16. Jantrapirom S, Nimlamool W, Chattipakorn N, Chattipakorn S, Temviriyanukul P, Inthachat W, et al. Liraglutide suppresses tau hyperphosphorylation, amyloid beta accumulation through regulating neuronal insulin signaling and BACE-1 activity. Int J Mol Sci. 2020;21(5):1725. doi:10.3390/ijms21051725.
17. Batista AF, Forny-Germano L, Clarke JR, Lyra e Silva NM, Brito-Moreira J, Boehnke SE, et al. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer’s disease. J Pathol. 2018;245(1):85–100. doi:10.1002/path.5056
18. Hunter K, Hölscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33. doi:10.1186/1471-2202-13-33.
19. Du H, Meng X, Yao Y, Xu J. The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease. Front Endocrinol (Lausanne). 2022 Nov 17;13:1033479. doi:10.3389/fendo.2022.1033479.
20. Wang W, Wang QQ, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with first-time diagnosis of Alzheimer’s disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024;20(12):8661-72. doi:10.1002/alz.14313.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Paweł Jan Kuna, Konrad Borowski, Laura Chmielowiec , Maja Radziwon, Wojciech Kuna, Alicja Chojniak, Zuzanna Łyko, Michał Tomaszek, Agnieszka Benecka, Artur Sikora
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 18
Number of citations: 0
